Aromatase Deficiency

Mendelian MONDO:0013301 Pathograph 37 Show in embeddings browser Endocrine Disorder Inborn Error of Metabolism

Aromatase deficiency is a rare autosomal recessive disorder caused by biallelic CYP19A1 loss-of-function variants. Deficient aromatase activity impairs conversion of androgen precursors to estrogens, producing congenital estrogen deficiency with androgen excess. The phenotype is sex- and age- dependent: 46,XX individuals can present with maternal antenatal virilization, ambiguous genitalia, hypergonadotropic hypogonadism, poor pubertal development, primary amenorrhea, and ovarian cysts, while 46,XY individuals can present later with tall stature, delayed skeletal maturation, osteoporosis, and metabolic impairment.

Ask OpenScientist

Ask a research question about Aromatase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
26
Phenotypes
37
Pathograph
1
Genes
1
Medical Actions
2
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Aromatase deficiency results from biallelic loss-of-function variants in CYP19A1 and follows autosomal recessive inheritance.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:35837780 SUPPORT Human Clinical
"Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome."
The case report directly states the autosomal recessive, CYP19A1 loss-of-function basis of aromatase deficiency.
ORPHA:91 SUPPORT Other
"Autosomal recessive"
Orphanet independently records autosomal recessive inheritance.
⚙

Pathophysiology

5
CYP19A1 Loss-of-Function and Aromatase Deficiency
Biallelic loss-of-function variants in CYP19A1 reduce or abolish aromatase activity. Aromatase normally catalyzes androgen-to-estrogen conversion in the placenta, gonads, adipose tissue, and other estrogen-producing tissues.
granulosa cell CL:0000501 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves granulosa cell (CL:0000501). CL:0000501 is a cell type from the Cell Ontology. trophoblast cell CL:0000351 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves trophoblast cell (CL:0000351). CL:0000351 is a cell type from the Cell Ontology. Leydig cell CL:0000178 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Leydig cell (CL:0000178). CL:0000178 is a cell type from the Cell Ontology. adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology.
CYP19A1 hgnc:2594 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CYP19A1 (hgnc:2594). hgnc:2594 is a gene from the HUGO Gene Nomenclature Committee.
steroid biosynthetic process GO:0006694 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal steroid biosynthetic process (GO:0006694). GO:0006694 is a biological process from the Gene Ontology. ⚠ ABNORMAL estrogen biosynthetic process GO:0006703 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased estrogen biosynthetic process (GO:0006703). GO:0006703 is a biological process from the Gene Ontology. ↓ DECREASED androgen metabolic process GO:0008209 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal androgen metabolic process (GO:0008209). GO:0008209 is a biological process from the Gene Ontology. ⚠ ABNORMAL
aromatase activity GO:0070330 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased aromatase activity (GO:0070330). GO:0070330 is a molecular function from the Gene Ontology. ↓ DECREASED
ovary UBERON:0000992 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ovary (UBERON:0000992). UBERON:0000992 is an anatomical location from the Uberon multi-species anatomy ontology. placenta UBERON:0001987 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in placenta (UBERON:0001987). UBERON:0001987 is an anatomical location from the Uberon multi-species anatomy ontology. testis UBERON:0000473 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in testis (UBERON:0000473). UBERON:0000473 is an anatomical location from the Uberon multi-species anatomy ontology. adipose tissue UBERON:0001013 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adipose tissue (UBERON:0001013). UBERON:0001013 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Estrogen Deficiency and Androgen Excess Reduced aromatase activity blocks androgen-to-estrogen conversion, lowering estrogen synthesis while leaving androgen precursors relatively excessive.
Show evidence (3 references)
PMID:35837780 SUPPORT Human Clinical
"Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome."
Directly supports biallelic CYP19A1 loss of function as the proximal cause of congenital estrogen deficiency.
PMID:24705274 SUPPORT Human Clinical
"P450 aromatase (CYP19A1) is essential for the biosynthesis of estrogens from androgen precursors. Mutations in the coding region of CYP19A1 lead to autosomal recessive aromatase deficiency."
Establishes CYP19A1 aromatase as the enzyme required for estrogen biosynthesis from androgen precursors.
PMID:14968547 SUPPORT Other
"Aromatase, a key enzyme in estrogen synthesis, is tissue-specifically regulated in various tissues and plays an important role through endocrine and intracrine estrogen production in various physiological functions."
Review-level evidence supports aromatase as a tissue-regulated enzyme required for endocrine and intracrine estrogen production.
Estrogen Deficiency and Androgen Excess
Loss of aromatase causes systemic estrogen deficiency and relative androgen excess. This disrupts genital differentiation, puberty, gonadotropin feedback, skeletal maturation, bone mass accrual, and metabolic regulation.
estrogen receptor signaling pathway GO:0030520 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased estrogen receptor signaling pathway (GO:0030520). GO:0030520 is a biological process from the Gene Ontology. ↓ DECREASED gonadotropin secretion GO:0032274 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased gonadotropin secretion (GO:0032274). GO:0032274 is a biological process from the Gene Ontology. ↑ INCREASED
uterus UBERON:0000995 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in uterus (UBERON:0000995). UBERON:0000995 is an anatomical location from the Uberon multi-species anatomy ontology. brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Maternal Antenatal Virilization Failure of fetal-placental aromatization exposes the pregnant mother to excess androgens, producing antenatal virilization during affected pregnancies.
Gonadotropin Feedback and Reproductive Development Disruption Low estrogen weakens reproductive-tissue maturation and negative feedback on the hypothalamic-pituitary-gonadal axis.
Impaired Skeletal Maturation and Bone Remodeling Estrogen deficiency delays epiphyseal closure and impairs bone mineral accrual, causing delayed skeletal maturation and low bone mass.
Metabolic Effects of Estrogen Deficiency Estrogen deficiency can affect glucose-insulin physiology and broader metabolic regulation, although the precise tissue mechanisms remain less resolved than the reproductive and skeletal manifestations.
Show evidence (2 references)
PMID:18448329 SUPPORT Human Clinical
"Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated."
Summarizes the core endocrine state: absent estrogen synthesis with gonadotropins and testosterone ranging from normal to elevated.
PMID:19844120 SUPPORT Human Clinical
"After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture."
Supports the combined estrogen-deficiency and androgen-excess mechanism.
Gonadotropin Feedback and Reproductive Development Disruption
Insufficient estrogen signaling disrupts pubertal maturation and removes normal gonadotropin feedback, while androgen excess drives virilization in 46,XX individuals. Elevated FSH and ovarian cysts are frequent diagnostic clues in 46,XX aromatase deficiency.
granulosa cell CL:0000501 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves granulosa cell (CL:0000501). CL:0000501 is a cell type from the Cell Ontology.
gonadotropin secretion GO:0032274 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased gonadotropin secretion (GO:0032274). GO:0032274 is a biological process from the Gene Ontology. ↑ INCREASED sex differentiation GO:0007548 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal sex differentiation (GO:0007548). GO:0007548 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Ambiguous Genitalia Prenatal androgen excess in 46,XX fetuses produces virilized or ambiguous external genitalia.
Clitoromegaly Clitoral enlargement is a specific manifestation of 46,XX prenatal and postnatal androgen excess.
Hypergonadotropic Hypogonadism Low estrogen feedback contributes to elevated gonadotropins with impaired gonadal function.
Delayed Puberty Estrogen insufficiency impairs normal pubertal development and secondary sexual-characteristic development.
Primary Amenorrhea Estrogen deficiency prevents normal endometrial and pubertal maturation, causing primary amenorrhea in affected 46,XX individuals.
Ovarian Cysts Elevated gonadotropins and ovarian androgens promote ovarian cyst formation in 46,XX aromatase deficiency.
Female infertility Estrogen deficiency and disrupted ovarian development impair fertility in affected 46,XX individuals.
Male infertility Estrogen-deficient reproductive and gonadal maturation can impair fertility in affected 46,XY individuals.
Generalized Hirsutism Persistent androgen excess can produce generalized terminal-hair growth in affected 46,XX individuals.
Cryptorchidism Cryptorchidism is reported in the 46,XY reproductive spectrum, although the intermediate developmental mechanism is not established.
Postpubertal Macroorchidism Increased testicular volume can emerge after puberty in affected 46,XY individuals; the causal intermediates remain incompletely resolved.
Show evidence (2 references)
PMID:11305285 SUPPORT Human Clinical
"It gives rise to ambiguous genitalia in 46,XX individuals. At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
Supports 46,XX genital, gonadotropin, and pubertal manifestations.
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
Case series plus systematic review provides frequency counts for 46,XX reproductive and hormonal manifestations.
Impaired Skeletal Maturation and Bone Remodeling
Estrogen deficiency delays epiphyseal closure and skeletal maturation, extends linear growth, and impairs attainment of peak bone mass, producing tall stature, unfused epiphyses, delayed bone age, osteopenia, and osteoporosis.
osteoblast CL:0000062 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoblast (CL:0000062). CL:0000062 is a cell type from the Cell Ontology. osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
bone remodeling GO:0046849 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal bone remodeling (GO:0046849). GO:0046849 is a biological process from the Gene Ontology. ⚠ ABNORMAL endochondral ossification GO:0001958 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal endochondral ossification (GO:0001958). GO:0001958 is a biological process from the Gene Ontology. ⚠ ABNORMAL
bone tissue UBERON:0002481 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in bone tissue (UBERON:0002481). UBERON:0002481 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Delayed Skeletal Maturation Lack of estrogen-mediated epiphyseal maturation delays bone age.
Delayed epiphyseal ossification Impaired estrogen-dependent epiphyseal maturation delays epiphyseal ossification.
Tall Stature Delayed epiphyseal closure permits persistent linear growth into adulthood, particularly in 46,XY affected individuals.
Osteoporosis Impaired estrogen-dependent bone remodeling and peak bone mass accrual cause osteopenia or osteoporosis.
Osteopenia Reduced estrogen signaling can impair bone mass accrual before reaching the osteoporosis threshold.
Eunuchoid Habitus Delayed epiphyseal closure permits disproportionate appendicular growth, producing eunuchoid skeletal proportions, particularly in 46,XY adults.
Bone Pain Low bone mass and skeletal fragility can manifest as bone pain and recurrent low-trauma fractures.
Genu Valgum Genu valgum is part of the reported skeletal spectrum, but its precise relationship to estrogen-dependent growth-plate maturation is unresolved.
Show evidence (2 references)
PMID:21874760 SUPPORT Other
"Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals."
Supports the skeletal maturation and bone-remodeling consequences of aromatase/estrogen deficiency.
PMID:18448329 SUPPORT Human Clinical
"The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment."
Summarizes the skeletal phenotype in aromatase-deficient males.
Metabolic Effects of Estrogen Deficiency
Aromatase-deficient individuals can show abnormalities of glucose-insulin physiology. The clinical literature supports metabolic involvement, but the precise intermediates between congenital estrogen deficiency and insulin resistance remain incompletely defined.
adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology.
glucose homeostasis GO:0042593 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal glucose homeostasis (GO:0042593). GO:0042593 is a biological process from the Gene Ontology. ⚠ ABNORMAL insulin receptor signaling pathway GO:0008286 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal insulin receptor signaling pathway (GO:0008286). GO:0008286 is a biological process from the Gene Ontology. ⚠ ABNORMAL
adipose tissue UBERON:0001013 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adipose tissue (UBERON:0001013). UBERON:0001013 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Insulin Resistance Estrogen-deficiency effects on glucose metabolism can manifest as reduced insulin sensitivity.
Obesity Estrogen-deficient metabolic dysregulation can include excess adiposity, although the responsible tissue intermediates are not established.
Acanthosis Nigricans Acanthosis nigricans can accompany the insulin-resistant metabolic phenotype of congenital estrogen deficiency.
Hyperlipidemia Dyslipidemia can accompany the metabolic effects of congenital estrogen deficiency.
Hepatic Steatosis Hepatic steatosis can accompany the broader metabolic phenotype, but the estrogen-dependent liver intermediates remain unresolved.
Type II Diabetes Mellitus Type II diabetes is reported in the metabolic spectrum, but progression from insulin resistance is incompletely characterized in this ultra-rare disorder.
Show evidence (2 references)
PMID:18448329 SUPPORT Human Clinical
"These phenotypes suggest the physiological role of estrogens on the skeleton, on pituitary function, on the reproductive system, on glucose metabolism, being the precise mechanism on each of these functions not yet known in detail."
Review-level evidence supports glucose-metabolism involvement while acknowledging unresolved intermediates.
PMID:19844120 SUPPORT Human Clinical
"Insulin sensitivity may be abnormal in both men and women."
Supports insulin-sensitivity abnormality across sexes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Aromatase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

26
Digestive 1
Hepatic Steatosis FREQUENT HP:0001397 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatic steatosis (HP:0001397). HP:0001397 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8)."
The clinical review lists non-alcoholic fatty liver.
ORPHA:91 SUPPORT Other
"HP:0001397 | Hepatic steatosis | Frequent (79-30%)"
Orphanet supplies the frequent band.
Endocrine 3
Delayed Puberty HP:0000823 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed puberty (HP:0000823). HP:0000823 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11305285 SUPPORT Human Clinical
"At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
Supports pubertal failure/poor pubertal development in 46,XX individuals.
Hypergonadotropic Hypogonadism VERY_FREQUENT HP:0000815 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypergonadotropic hypogonadism (HP:0000815). HP:0000815 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:11305285 SUPPORT Human Clinical
"At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
Directly supports hypergonadotropic hypogonadism at puberty in affected girls.
ORPHA:91 SUPPORT Other
"HP:0000815 | Hypergonadotropic hypogonadism | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Type II Diabetes Mellitus FREQUENT HP:0005978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Type II diabetes mellitus (HP:0005978). HP:0005978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0005978 | Type II diabetes mellitus | Frequent (79-30%)"
Orphanet records type II diabetes mellitus as frequent.
Genitourinary 5
Clitoromegaly Clitoral hypertrophy HP:0008665 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clitoral hypertrophy (HP:0008665). HP:0008665 is a phenotype from the Human Phenotype Ontology.
Component of 46,XX virilization.
Show evidence (1 reference)
PMID:24482950 SUPPORT Human Clinical
"She lacked feminine secondary sexual characters, had eunuchoid body habitus and prominent clitoromegaly."
Human case report directly supports prominent clitoromegaly in a 46,XX affected individual.
Primary Amenorrhea VERY_FREQUENT HP:0000786 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Primary amenorrhea (HP:0000786). HP:0000786 is a phenotype from the Human Phenotype Ontology.
In 46,XX individuals.
Show evidence (2 references)
PMID:18448329 SUPPORT Human Clinical
"At puberty they show primary amenorrhea, no breast development, worsening of the virilization and the absence of growth spurt."
Directly supports primary amenorrhea in affected females at puberty.
ORPHA:91 SUPPORT Other
"HP:0000786 | Primary amenorrhea | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Female infertility VERY_FREQUENT HP:0008222 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Female infertility (HP:0008222). HP:0008222 is a phenotype from the Human Phenotype Ontology.
In 46,XX individuals.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0008222 | Female infertility | Very frequent (99-80%)"
Orphanet reports female infertility as very frequent.
Male infertility VERY_FREQUENT HP:0003251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Male infertility (HP:0003251). HP:0003251 is a phenotype from the Human Phenotype Ontology.
In 46,XY individuals.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0003251 | Male infertility | Very frequent (99-80%)"
Orphanet reports male infertility as very frequent.
Cryptorchidism VERY_FREQUENT HP:0000028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cryptorchidism (HP:0000028). HP:0000028 is a phenotype from the Human Phenotype Ontology.
In affected 46,XY individuals.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present."
The clinical review within the case report lists cryptorchidism.
ORPHA:91 SUPPORT Other
"HP:0000028 | Cryptorchidism | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Integument 1
Acanthosis Nigricans FREQUENT HP:0000956 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acanthosis nigricans (HP:0000956). HP:0000956 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8)."
The clinical review lists acanthosis nigricans.
ORPHA:91 SUPPORT Other
"HP:0000956 | Acanthosis nigricans | Frequent (79-30%)"
Orphanet supplies the frequent band.
Limbs 1
Genu Valgum VERY_FREQUENT HP:0002857 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Genu valgum (HP:0002857). HP:0002857 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Clinical and radiological findings include delay in bone maturation, lack of epiphyseal closure, continuation of linear growth, tall stature, eunuchoid body habitus, genu valgum, bone pain, osteopenia, and osteoporosis."
The clinical review within the case report lists genu valgum.
ORPHA:91 SUPPORT Other
"HP:0002857 | Genu valgum | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Metabolism 2
Insulin Resistance FREQUENT HP:0000855 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insulin resistance (HP:0000855). HP:0000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:19844120 SUPPORT Human Clinical
"Insulin sensitivity may be abnormal in both men and women."
Supports abnormal insulin sensitivity as a metabolic manifestation.
ORPHA:91 SUPPORT Other
"HP:0000855 | Insulin resistance | Frequent (79-30%)"
Orphanet supplies the frequent band.
Hyperlipidemia VERY_FREQUENT HP:0003077 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperlipidemia (HP:0003077). HP:0003077 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8)."
The clinical review lists dyslipidemia.
ORPHA:91 SUPPORT Other
"HP:0003077 | Hyperlipidemia | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Musculoskeletal 4
Delayed Skeletal Maturation VERY_FREQUENT HP:0002750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed skeletal maturation (HP:0002750). HP:0002750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
Systematic-review data support delayed bone age as a frequent skeletal finding.
Delayed epiphyseal ossification VERY_FREQUENT HP:0002663 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed epiphyseal ossification (HP:0002663). HP:0002663 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0002663 | Delayed epiphyseal ossification | Very frequent (99-80%)"
Orphanet reports delayed epiphyseal ossification as very frequent.
Osteoporosis VERY_FREQUENT HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
The 5/8 count supports the low-bone-mass spectrum in reported 46,XX cases but does not distinguish osteopenia from osteoporosis.
PMID:18448329 SUPPORT Human Clinical
"The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment."
Review-level human evidence supports osteopenia/osteoporosis in affected males.
ORPHA:91 SUPPORT Other
"HP:0000939 | Osteoporosis | Very frequent (99-80%)"
Orphanet supplies the phenotype-specific very-frequent band.
Osteopenia VERY_FREQUENT HP:0000938 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteopenia (HP:0000938). HP:0000938 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0000938 | Osteopenia | Very frequent (99-80%)"
Orphanet reports osteopenia as very frequent.
Constitutional 1
Bone Pain VERY_FREQUENT HP:0002653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone pain (HP:0002653). HP:0002653 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Our patient was a 27-year-old male who presented with bone pain, recurrent bone fractures associated with minimal trauma starting in puberty, and a progressive increase in height."
An affected adult presented with bone pain and recurrent low-trauma fractures.
ORPHA:91 SUPPORT Other
"HP:0002653 | Bone pain | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Growth 2
Tall Stature VERY_FREQUENT HP:0000098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tall stature (HP:0000098). HP:0000098 is a phenotype from the Human Phenotype Ontology.
Most characteristic in affected 46,XY individuals.
Show evidence (2 references)
PMID:11305285 SUPPORT Human Clinical
"These men are extremely tall and have eunuchoid proportions with continued linear growth into adulthood, lack of epiphyseal closure, and osteoporosis due to estrogen deficiency."
Directly supports tall stature from continued linear growth in aromatase-deficient men.
ORPHA:91 SUPPORT Other
"HP:0000098 | Tall stature | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Obesity VERY_FREQUENT HP:0001513 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8)."
The clinical review lists abdominal obesity in the metabolic spectrum.
ORPHA:91 SUPPORT Other
"HP:0001513 | Obesity | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
Other 6
Ambiguous Genitalia VERY_FREQUENT Ambiguous genitalia, female HP:0000061 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ambiguous genitalia, female (HP:0000061). HP:0000061 is a phenotype from the Human Phenotype Ontology.
In 46,XX individuals.
Show evidence (1 reference)
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
Systematic review count supports ambiguous genitalia as very frequent in genetically confirmed 46,XX aromatase deficiency.
Maternal Antenatal Virilization FREQUENT
Maternal manifestation during pregnancy with an affected fetus.
Show evidence (2 references)
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
The systematic review count supports maternal antenatal virilization as a frequent presentation associated with aromatase deficiency pregnancies.
PMID:40321354 SUPPORT Human Clinical
"A 10-day-old newborn presented with atypical genitalia and a history of maternal virilization during pregnancy."
Case-report evidence documents maternal virilization during pregnancy in an infant with genetically confirmed aromatase deficiency.
Ovarian Cysts FREQUENT HP:0000138 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ovarian cyst (HP:0000138). HP:0000138 is a phenotype from the Human Phenotype Ontology.
In 46,XX individuals.
Show evidence (1 reference)
PMID:32623730 SUPPORT Human Clinical
"The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
The 13/30 ovarian-cyst frequency supports the FREQUENT band.
Generalized Hirsutism FREQUENT HP:0002230 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized hirsutism (HP:0002230). HP:0002230 is a phenotype from the Human Phenotype Ontology.
Most relevant to the androgen-excess phenotype in 46,XX individuals.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"HP:0002230 | Generalized hirsutism | Frequent (79-30%)"
Orphanet records generalized hirsutism as frequent.
Postpubertal Macroorchidism FREQUENT Macroorchidism, postpubertal HP:0002050 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macroorchidism, postpubertal (HP:0002050). HP:0002050 is a phenotype from the Human Phenotype Ontology.
In affected postpubertal 46,XY individuals.
Show evidence (2 references)
PMID:23748068 SUPPORT Human Clinical
"Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present."
The clinical review within the case report describes increased testicular volume.
ORPHA:91 SUPPORT Other
"HP:0002050 | Macroorchidism, postpubertal | Frequent (79-30%)"
Orphanet supplies the frequent band.
Eunuchoid Habitus VERY_FREQUENT HP:0003782 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eunuchoid habitus (HP:0003782). HP:0003782 is a phenotype from the Human Phenotype Ontology.
Most characteristic in affected 46,XY adults.
Show evidence (2 references)
PMID:19707181 SUPPORT Human Clinical
"At presentation, all men with aromatase deficiency have tall stature, delayed bone maturation, osteopenia or osteoporosis and eunuchoid skeletal proportions."
The male clinical review directly supports eunuchoid proportions.
ORPHA:91 SUPPORT Other
"HP:0003782 | Eunuchoid habitus | Very frequent (99-80%)"
Orphanet supplies the very-frequent band.
🧬

Genetic Associations

1
CYP19A1
Gene: CYP19A1 hgnc:2594 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CYP19A1 (hgnc:2594). hgnc:2594 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:40321354 SUPPORT Human Clinical
"Aromatase deficiency is a rare autosomal recessive condition due to a mutation in the CYP19A1 encoding aromatase enzyme."
Confirms CYP19A1 variants as the cause of aromatase deficiency.
PMID:34348419 SUPPORT Human Clinical
"Our proband is an Old Order Mennonite female born with ambiguous genitalia who was identified to carry novel homozygous variant in the CYP19A1 gene c.1304G>A (p. Arg435His)."
Reports a homozygous CYP19A1 variant in an affected individual.
💊

Medical Actions

1
Estrogen Replacement Therapy
Category: Therapeutic Action: Estrogen Replacement TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Estrogen Replacement Therapy (NCIT:C15231). NCIT:C15231 is a clinical intervention from the NCI Thesaurus. NCIT:C15231
Agent: estradiol CHEBI:23965 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses estradiol (CHEBI:23965). CHEBI:23965 is a therapeutic agent from Chemical Entities of Biological Interest.
Estradiol replacement restores estrogen exposure, supports skeletal maturation and epiphyseal closure, and is the central disease-directed therapy once aromatase deficiency is diagnosed.
Mechanism Target:
RESTORES Estrogen Deficiency and Androgen Excess — Estradiol replacement restores downstream estrogen exposure despite persistent CYP19A1 deficiency.
Show evidence (1 reference)
PMID:18448329 SUPPORT Human Clinical
"The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
Clinical response to estradiol replacement supports restoration of estrogen-dependent downstream physiology.
RESTORES Impaired Skeletal Maturation and Bone Remodeling — Estradiol replacement promotes epiphyseal closure and skeletal maturation.
Show evidence (1 reference)
PMID:18448329 SUPPORT Human Clinical
"The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
Directly supports restoration of skeletal maturation with estradiol replacement.
Target Phenotypes: Delayed skeletal maturation HP:0002750 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Delayed skeletal maturation (HP:0002750). HP:0002750 is a phenotype from the Human Phenotype Ontology. Osteopenia HP:0000938 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Osteopenia (HP:0000938). HP:0000938 is a phenotype from the Human Phenotype Ontology. Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:18448329 SUPPORT Human Clinical
"The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
Supports estradiol replacement as disease-directed therapy for skeletal maturation.
PMID:19707181 SUPPORT Human Clinical
"Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy."
Clinical review supports lifelong estradiol replacement therapy in affected males.
🔬

Biochemical Markers

4
Serum Estradiol (DECREASED)
Context: Estradiol is very low or undetectable because aromatase cannot efficiently convert androgens to estrogens.
Pathograph Readouts
Readout Of CYP19A1 Loss-of-Function and Aromatase Deficiency Negative Diagnostic
Very low or undetectable estradiol reports the aromatase enzyme block.
Show evidence (1 reference)
PMID:35837780 SUPPORT Human Clinical
"His estradiol was below the measurable line, the follicle-stimulating hormone (FSH) increased, bone age delayed, epiphysis unfused, and the bone mass reduced."
Undetectable estradiol directly reports the aromatase block.
Readout Of Estrogen Deficiency and Androgen Excess Negative Diagnostic
Low serum estradiol directly reports the estrogen-deficient endocrine state.
Show evidence (1 reference)
PMID:18448329 SUPPORT Human Clinical
"Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated."
The review directly links the genotype to absent estrogen synthesis.
Show evidence (2 references)
PMID:35837780 SUPPORT Human Clinical
"His estradiol was below the measurable line, the follicle-stimulating hormone (FSH) increased, bone age delayed, epiphysis unfused, and the bone mass reduced."
Human case report supports very low estradiol with elevated FSH and skeletal findings.
PMID:19707181 SUPPORT Human Clinical
"Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
Review-level clinical guidance supports undetectable serum estradiol as a diagnostic biochemical feature.
Serum Testosterone (INCREASED)
Context: Testosterone is normal to elevated because androgen precursors are not efficiently aromatized to estrogens.
Pathograph Readouts
Readout Of Estrogen Deficiency and Androgen Excess Positive Diagnostic
Normal-to-elevated circulating testosterone reports androgen excess from failed aromatization.
Show evidence (1 reference)
PMID:18448329 SUPPORT Human Clinical
"Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated."
The review directly supports normal-to-elevated circulating testosterone.
Show evidence (1 reference)
PMID:18448329 SUPPORT Human Clinical
"Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated."
Supports normal-to-elevated testosterone in aromatase deficiency.
Serum Follicle-Stimulating Hormone (INCREASED)
Context: FSH can be elevated because low estrogen weakens negative feedback on the hypothalamic-pituitary-gonadal axis.
Pathograph Readouts
Readout Of Gonadotropin Feedback and Reproductive Development Disruption Positive Diagnostic
Elevated serum FSH reports disrupted gonadal feedback.
Show evidence (1 reference)
PMID:23748068 SUPPORT Human Clinical
"Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable."
The affected adult had serum FSH above normal.
Show evidence (1 reference)
PMID:23748068 SUPPORT Human Clinical
"Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable."
The affected adult had serum FSH above normal.
Serum Luteinizing Hormone (INCREASED)
Context: LH can be elevated because low estrogen weakens negative feedback on the hypothalamic-pituitary-gonadal axis.
Pathograph Readouts
Readout Of Gonadotropin Feedback and Reproductive Development Disruption Positive Diagnostic
Elevated serum LH reports disrupted gonadal feedback.
Show evidence (1 reference)
PMID:23748068 SUPPORT Human Clinical
"Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable."
The affected adult had serum LH above normal.
Show evidence (1 reference)
PMID:23748068 SUPPORT Human Clinical
"Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable."
The affected adult had serum LH above normal.
🔬

Diagnosis

1
CYP19A1 Sequencing and Endocrine Profile (Positive in affected individuals)
Diagnosis is supported by low or undetectable estradiol, elevated gonadotropins or androgen excess depending on age and sex, and confirmation by CYP19A1 sequencing.
Show evidence (2 references)
PMID:19707181 SUPPORT Human Clinical
"Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
Supports the combined biochemical, skeletal, and genetic diagnostic approach.
PMID:25415177 SUPPORT Human Clinical
"Direct sequencing of the CYP19A1 gene from genomic DNA revealed one novel mutation (c.574C>T) in two patients."
Demonstrates diagnostic CYP19A1 sequencing in affected 46,XX patients.
📈

Progression

1
Onset
Age: Fetal life-adulthood
Show evidence (2 references)
PMID:19844120 SUPPORT Human Clinical
"Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture."
Review-level evidence supports prenatal and postnatal manifestations from the same androgen-excess/estrogen-deficiency mechanism.
PMID:24705274 SUPPORT Human Clinical
"To date over 20 subjects have been reported with aromatase deficiency which may manifest during fetal life with maternal virilization and virilization of the external genitalia of a female fetus due to low aromatase activity in the steroid metabolizing fetal-placental unit and thus high androgen levels."
Human case-report literature supports fetal-life manifestations caused by low aromatase activity in the fetal-placental unit.
📊

Prevalence

1
Worldwide
Point Prevalence ≤0.1 per 100,000 <1 in 1,000,000
Orphanet reports worldwide point prevalence below one per million.
Show evidence (1 reference)
ORPHA:91 SUPPORT Other
"<1 / 1 000 000 | Worldwide | Point prevalence | PMID:27256151,PMID:27693882,PMID:29324451,PMID:29553041"
Orphanet supplies the structured worldwide point-prevalence class.
{ }

Source YAML

click to show 
name: Aromatase Deficiency
creation_date: "2025-12-04T16:57:31Z"
description: >-
  Aromatase deficiency is a rare autosomal recessive disorder caused by
  biallelic CYP19A1 loss-of-function variants. Deficient aromatase activity
  impairs conversion of androgen precursors to estrogens, producing congenital
  estrogen deficiency with androgen excess. The phenotype is sex- and age-
  dependent: 46,XX individuals can present with maternal antenatal virilization,
  ambiguous genitalia, hypergonadotropic hypogonadism, poor pubertal
  development, primary amenorrhea, and ovarian cysts, while 46,XY individuals
  can present later with tall stature, delayed skeletal maturation,
  osteoporosis, and metabolic impairment.
category: Mendelian
parents:
- Endocrine Disorder
- Inborn Error of Metabolism
disease_term:
  preferred_term: aromatase deficiency
  description: >-
    A rare autosomal recessive disorder caused by CYP19A1 mutations resulting
    in inability to convert androgens to estrogens.
  term:
    id: MONDO:0013301
    label: aromatase deficiency
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Aromatase deficiency results from biallelic loss-of-function variants in
    CYP19A1 and follows autosomal recessive inheritance.
  evidence:
  - reference: PMID:35837780
    reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome.
    explanation: >-
      The case report directly states the autosomal recessive, CYP19A1
      loss-of-function basis of aromatase deficiency.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Autosomal recessive
    explanation: Orphanet independently records autosomal recessive inheritance.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_high: 0.1
  notes: Orphanet reports worldwide point prevalence below one per million.
  evidence:
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      <1 / 1 000 000 | Worldwide | Point prevalence | PMID:27256151,PMID:27693882,PMID:29324451,PMID:29553041
    explanation: >-
      Orphanet supplies the structured worldwide point-prevalence class.
progression:
- phase: Onset
  age_range: Fetal life-adulthood
  evidence:
  - reference: PMID:19844120
    reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture.
    explanation: >-
      Review-level evidence supports prenatal and postnatal manifestations from
      the same androgen-excess/estrogen-deficiency mechanism.
  - reference: PMID:24705274
    reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date over 20 subjects have been reported with aromatase deficiency which may manifest during fetal life with maternal virilization and virilization of the external genitalia of a female fetus due to low aromatase activity in the steroid metabolizing fetal-placental unit and thus high androgen levels.
    explanation: >-
      Human case-report literature supports fetal-life manifestations caused by
      low aromatase activity in the fetal-placental unit.
pathophysiology:
- name: CYP19A1 Loss-of-Function and Aromatase Deficiency
  description: >-
    Biallelic loss-of-function variants in CYP19A1 reduce or abolish aromatase
    activity. Aromatase normally catalyzes androgen-to-estrogen conversion in
    the placenta, gonads, adipose tissue, and other estrogen-producing tissues.
  role: Primary
  biological_scale: MOLECULAR
  genes:
  - preferred_term: CYP19A1
    term:
      id: hgnc:2594
      label: CYP19A1
  cell_types:
  - preferred_term: granulosa cell
    description: Ovarian site of aromatase expression for estrogen synthesis.
    term:
      id: CL:0000501
      label: granulosa cell
  - preferred_term: trophoblast cell
    description: Placental aromatase site; loss causes maternal and fetal virilization.
    term:
      id: CL:0000351
      label: trophoblast cell
  - preferred_term: Leydig cell
    description: Testicular androgen source; aromatization affects systemic hormone balance.
    term:
      id: CL:0000178
      label: Leydig cell
  - preferred_term: adipocyte
    description: Peripheral aromatase expression site contributing to local estrogen production.
    term:
      id: CL:0000136
      label: adipocyte
  molecular_functions:
  - preferred_term: aromatase activity
    modifier: DECREASED
    term:
      id: GO:0070330
      label: aromatase activity
  biological_processes:
  - preferred_term: steroid biosynthetic process
    modifier: ABNORMAL
    term:
      id: GO:0006694
      label: steroid biosynthetic process
  - preferred_term: estrogen biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0006703
      label: estrogen biosynthetic process
  - preferred_term: androgen metabolic process
    modifier: ABNORMAL
    term:
      id: GO:0008209
      label: androgen metabolic process
  chemical_entities:
  - preferred_term: estradiol
    modifier: DECREASED
    term:
      id: CHEBI:23965
      label: estradiol
  - preferred_term: testosterone
    modifier: INCREASED
    term:
      id: CHEBI:17347
      label: testosterone
  locations:
  - preferred_term: ovary
    description: Site of granulosa aromatase; ovarian development and fertility are affected.
    term:
      id: UBERON:0000992
      label: ovary
  - preferred_term: placenta
    description: Crucial fetal-placental estrogen-production site.
    term:
      id: UBERON:0001987
      label: placenta
  - preferred_term: testis
    description: Androgen source; 46,XY genital phenotype is often milder than 46,XX.
    term:
      id: UBERON:0000473
      label: testis
  - preferred_term: adipose tissue
    description: Peripheral aromatization site.
    term:
      id: UBERON:0001013
      label: adipose tissue
  evidence:
  - reference: PMID:35837780
    reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome.
    explanation: >-
      Directly supports biallelic CYP19A1 loss of function as the proximal
      cause of congenital estrogen deficiency.
  - reference: PMID:24705274
    reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      P450 aromatase (CYP19A1) is essential for the biosynthesis of estrogens from androgen precursors. Mutations in the coding region of CYP19A1 lead to autosomal recessive aromatase deficiency.
    explanation: >-
      Establishes CYP19A1 aromatase as the enzyme required for estrogen
      biosynthesis from androgen precursors.
  - reference: PMID:14968547
    reference_title: "[Aromatase deficiency]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Aromatase, a key enzyme in estrogen synthesis, is tissue-specifically regulated in various tissues and plays an important role through endocrine and intracrine estrogen production in various physiological functions.
    explanation: >-
      Review-level evidence supports aromatase as a tissue-regulated enzyme
      required for endocrine and intracrine estrogen production.
  downstream:
  - target: Estrogen Deficiency and Androgen Excess
    description: >-
      Reduced aromatase activity blocks androgen-to-estrogen conversion, lowering
      estrogen synthesis while leaving androgen precursors relatively excessive.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
      explanation: >-
        Directly links inactivating aromatase variants to absent estrogen
        synthesis and normal-to-elevated testosterone.
- name: Estrogen Deficiency and Androgen Excess
  description: >-
    Loss of aromatase causes systemic estrogen deficiency and relative androgen
    excess. This disrupts genital differentiation, puberty, gonadotropin
    feedback, skeletal maturation, bone mass accrual, and metabolic regulation.
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: estrogen receptor signaling pathway
    modifier: DECREASED
    term:
      id: GO:0030520
      label: estrogen receptor signaling pathway
  - preferred_term: gonadotropin secretion
    modifier: INCREASED
    term:
      id: GO:0032274
      label: gonadotropin secretion
  chemical_entities:
  - preferred_term: estradiol
    modifier: DECREASED
    term:
      id: CHEBI:23965
      label: estradiol
  - preferred_term: testosterone
    modifier: INCREASED
    term:
      id: CHEBI:17347
      label: testosterone
  locations:
  - preferred_term: uterus
    description: Estrogen-dependent organ; hypoplasia and poor endometrial development may occur.
    term:
      id: UBERON:0000995
      label: uterus
  - preferred_term: brain
    description: Central estrogen actions regulate hypothalamic-pituitary-gonadal feedback.
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
    explanation: >-
      Summarizes the core endocrine state: absent estrogen synthesis with
      gonadotropins and testosterone ranging from normal to elevated.
  - reference: PMID:19844120
    reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture.
    explanation: >-
      Supports the combined estrogen-deficiency and androgen-excess mechanism.
  downstream:
  - target: Maternal Antenatal Virilization
    description: >-
      Failure of fetal-placental aromatization exposes the pregnant mother to
      excess androgens, producing antenatal virilization during affected
      pregnancies.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Excess androgens in the fetal-placental unit during pregnancy.
    evidence:
    - reference: PMID:40321354
      reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This enzyme protects the fetus and mother from excess androgens by converting them into estrogen.
      explanation: >-
        The case-report abstract directly supports maternal androgen exposure
        when CYP19A1 aromatization is deficient.
  - target: Gonadotropin Feedback and Reproductive Development Disruption
    description: >-
      Low estrogen weakens reproductive-tissue maturation and negative feedback
      on the hypothalamic-pituitary-gonadal axis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced estrogen receptor signaling in reproductive tissues and pituitary feedback circuits.
    evidence:
    - reference: PMID:11305285
      reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization.
      explanation: >-
        Review-level human evidence links aromatase deficiency to pubertal
        gonadotropin and reproductive-development disruption.
  - target: Impaired Skeletal Maturation and Bone Remodeling
    description: >-
      Estrogen deficiency delays epiphyseal closure and impairs bone mineral
      accrual, causing delayed skeletal maturation and low bone mass.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced estrogen signaling in growth plate and bone remodeling compartments.
    evidence:
    - reference: PMID:21874760
      reference_title: "Aromatase activity and bone loss."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals.
      explanation: >-
        Supports aromatase-derived estrogen as necessary for skeletal growth,
        epiphyseal closure, and bone remodeling.
  - target: Metabolic Effects of Estrogen Deficiency
    description: >-
      Estrogen deficiency can affect glucose-insulin physiology and broader
      metabolic regulation, although the precise tissue mechanisms remain less
      resolved than the reproductive and skeletal manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Estrogen-dependent regulation of glucose metabolism and adipose/gonadal signaling.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These phenotypes suggest the physiological role of estrogens on the skeleton, on pituitary function, on the reproductive system, on glucose metabolism, being the precise mechanism on each of these functions not yet known in detail.
      explanation: >-
        The review explicitly names glucose metabolism while noting that precise
        mechanisms are not fully resolved.
- name: Gonadotropin Feedback and Reproductive Development Disruption
  description: >-
    Insufficient estrogen signaling disrupts pubertal maturation and removes
    normal gonadotropin feedback, while androgen excess drives virilization in
    46,XX individuals. Elevated FSH and ovarian cysts are frequent diagnostic
    clues in 46,XX aromatase deficiency.
  biological_scale: ORGANISM
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: gonadotropin secretion
    modifier: INCREASED
    term:
      id: GO:0032274
      label: gonadotropin secretion
  - preferred_term: sex differentiation
    modifier: ABNORMAL
    term:
      id: GO:0007548
      label: sex differentiation
  evidence:
  - reference: PMID:11305285
    reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It gives rise to ambiguous genitalia in 46,XX individuals. At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization.
    explanation: >-
      Supports 46,XX genital, gonadotropin, and pubertal manifestations.
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30).
    explanation: >-
      Case series plus systematic review provides frequency counts for 46,XX
      reproductive and hormonal manifestations.
  downstream:
  - target: Ambiguous Genitalia
    description: >-
      Prenatal androgen excess in 46,XX fetuses produces virilized or ambiguous
      external genitalia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Fetal-placental aromatase deficiency and high androgen exposure.
    evidence:
    - reference: PMID:24705274
      reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        aromatase deficiency which may manifest during fetal life with maternal virilization and virilization of the external genitalia of a female fetus due to low aromatase activity in the steroid metabolizing fetal-placental unit and thus high androgen levels.
      explanation: >-
        Directly supports low fetal-placental aromatase activity causing 46,XX
        external genital virilization.
  - target: Clitoromegaly
    description: >-
      Clitoral enlargement is a specific manifestation of 46,XX prenatal and
      postnatal androgen excess.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Androgen-mediated virilization of 46,XX external genitalia.
    evidence:
    - reference: PMID:24482950
      reference_title: "Aromatase deficiency: an unusual cause for primary amenorrhea with virilization."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "She lacked feminine secondary sexual characters, had eunuchoid body habitus and prominent clitoromegaly."
      explanation: >-
        A human case report supports clitoromegaly as part of the virilized
        46,XX phenotype.
  - target: Hypergonadotropic Hypogonadism
    description: >-
      Low estrogen feedback contributes to elevated gonadotropins with impaired
      gonadal function.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of estrogen negative feedback on the hypothalamic-pituitary-gonadal axis.
    evidence:
    - reference: PMID:11305285
      reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
      explanation: >-
        Directly supports hypergonadotropic hypogonadism in pubertal affected
        girls.
  - target: Delayed Puberty
    description: >-
      Estrogen insufficiency impairs normal pubertal development and secondary
      sexual-characteristic development.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Insufficient estrogen-dependent pubertal maturation.
    evidence:
    - reference: PMID:19844120
      reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In pubertal girls, there is poor sexual development and abnormal virilization."
      explanation: >-
        Supports impaired pubertal development in affected girls.
  - target: Primary Amenorrhea
    description: >-
      Estrogen deficiency prevents normal endometrial and pubertal maturation,
      causing primary amenorrhea in affected 46,XX individuals.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Failure of estrogen-dependent uterine and pubertal maturation.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "At puberty they show primary amenorrhea, no breast development, worsening of the virilization and the absence of growth spurt."
      explanation: >-
        Directly supports primary amenorrhea at puberty.
  - target: Ovarian Cysts
    description: >-
      Elevated gonadotropins and ovarian androgens promote ovarian cyst
      formation in 46,XX aromatase deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Elevated ovarian androgens and gonadotropins.
    evidence:
    - reference: PMID:19844120
      reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In prepubertal aromatase deficient girls, high levels of ovarian androgens and gonadotropins facilitate the formation of ovarian cysts."
      explanation: >-
        Directly links androgen and gonadotropin excess to ovarian cyst
        formation.
  - target: Female infertility
    description: >-
      Estrogen deficiency and disrupted ovarian development impair fertility in
      affected 46,XX individuals.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - disrupted ovarian follicular maturation
    - estrogen-deficient reproductive tract maturation
    evidence:
    - reference: ORPHA:91
      reference_title: "Aromatase deficiency"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0008222 | Female infertility | Very frequent (99-80%)"
      explanation: Orphanet lists female infertility as a very frequent phenotype.
  - target: Male infertility
    description: >-
      Estrogen-deficient reproductive and gonadal maturation can impair
      fertility in affected 46,XY individuals.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:91
      reference_title: "Aromatase deficiency"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003251 | Male infertility | Very frequent (99-80%)"
      explanation: Orphanet lists male infertility as a very frequent phenotype.
  - target: Generalized Hirsutism
    description: >-
      Persistent androgen excess can produce generalized terminal-hair growth
      in affected 46,XX individuals.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Androgen action in pilosebaceous units.
    evidence:
    - reference: ORPHA:91
      reference_title: Aromatase deficiency
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002230 | Generalized hirsutism | Frequent (79-30%)"
      explanation: >-
        Orphanet supports the phenotype and its frequency; the androgen-action
        intermediate is a mechanistic interpretation of the endocrine state.
  - target: Cryptorchidism
    description: >-
      Cryptorchidism is reported in the 46,XY reproductive spectrum, although
      the intermediate developmental mechanism is not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present.
      explanation: The clinical review within the case report lists cryptorchidism.
  - target: Postpubertal Macroorchidism
    description: >-
      Increased testicular volume can emerge after puberty in affected 46,XY
      individuals; the causal intermediates remain incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present.
      explanation: The clinical review within the case report describes increased testicular volume.
- name: Impaired Skeletal Maturation and Bone Remodeling
  description: >-
    Estrogen deficiency delays epiphyseal closure and skeletal maturation,
    extends linear growth, and impairs attainment of peak bone mass, producing
    tall stature, unfused epiphyses, delayed bone age, osteopenia, and
    osteoporosis.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: bone remodeling
    modifier: ABNORMAL
    term:
      id: GO:0046849
      label: bone remodeling
  - preferred_term: endochondral ossification
    modifier: ABNORMAL
    term:
      id: GO:0001958
      label: endochondral ossification
  locations:
  - preferred_term: bone tissue
    term:
      id: UBERON:0002481
      label: bone tissue
  evidence:
  - reference: PMID:21874760
    reference_title: "Aromatase activity and bone loss."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals.
    explanation: >-
      Supports the skeletal maturation and bone-remodeling consequences of
      aromatase/estrogen deficiency.
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
    explanation: >-
      Summarizes the skeletal phenotype in aromatase-deficient males.
  downstream:
  - target: Delayed Skeletal Maturation
    description: >-
      Lack of estrogen-mediated epiphyseal maturation delays bone age.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32623730
      reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
      explanation: >-
        Supports delayed bone age as a common skeletal manifestation in 46,XX
        aromatase deficiency.
  - target: Delayed epiphyseal ossification
    description: >-
      Impaired estrogen-dependent epiphyseal maturation delays epiphyseal
      ossification.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:91
      reference_title: "Aromatase deficiency"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002663 | Delayed epiphyseal ossification | Very frequent (99-80%)"
      explanation: Orphanet lists delayed epiphyseal ossification as very frequent.
  - target: Tall Stature
    description: >-
      Delayed epiphyseal closure permits persistent linear growth into
      adulthood, particularly in 46,XY affected individuals.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Persistent growth plate activity from lack of estrogen-mediated epiphyseal closure.
    evidence:
    - reference: PMID:11305285
      reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These men are extremely tall and have eunuchoid proportions with continued linear growth into adulthood, lack of epiphyseal closure, and osteoporosis due to estrogen deficiency."
      explanation: >-
        Directly links estrogen deficiency to tall stature and persistent growth
        in 46,XY affected individuals.
  - target: Osteoporosis
    description: >-
      Impaired estrogen-dependent bone remodeling and peak bone mass accrual
      cause osteopenia or osteoporosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
      explanation: >-
        Directly supports osteopenia/osteoporosis in aromatase deficiency.
  - target: Osteopenia
    description: >-
      Reduced estrogen signaling can impair bone mass accrual before reaching
      the osteoporosis threshold.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:91
      reference_title: "Aromatase deficiency"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000938 | Osteopenia | Very frequent (99-80%)"
      explanation: Orphanet lists osteopenia as very frequent.
  - target: Eunuchoid Habitus
    description: >-
      Delayed epiphyseal closure permits disproportionate appendicular growth,
      producing eunuchoid skeletal proportions, particularly in 46,XY adults.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Persistent long-bone growth after the usual age of epiphyseal closure.
    evidence:
    - reference: PMID:19707181
      reference_title: "Aromatase deficiency in men: a clinical perspective."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        At presentation, all men with aromatase deficiency have tall stature, delayed bone maturation, osteopenia or osteoporosis and eunuchoid skeletal proportions.
      explanation: The clinical review directly reports eunuchoid skeletal proportions.
  - target: Bone Pain
    description: >-
      Low bone mass and skeletal fragility can manifest as bone pain and
      recurrent low-trauma fractures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced bone mineralization and skeletal fragility.
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Our patient was a 27-year-old male who presented with bone pain, recurrent bone fractures associated with minimal trauma starting in puberty, and a progressive increase in height.
      explanation: The affected adult presented with bone pain and recurrent low-trauma fractures.
  - target: Genu Valgum
    description: >-
      Genu valgum is part of the reported skeletal spectrum, but its precise
      relationship to estrogen-dependent growth-plate maturation is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Clinical and radiological findings include delay in bone maturation, lack of epiphyseal closure, continuation of linear growth, tall stature, eunuchoid body habitus, genu valgum, bone pain, osteopenia, and osteoporosis.
      explanation: The clinical review within the case report lists genu valgum.
- name: Metabolic Effects of Estrogen Deficiency
  description: >-
    Aromatase-deficient individuals can show abnormalities of glucose-insulin
    physiology. The clinical literature supports metabolic involvement, but the
    precise intermediates between congenital estrogen deficiency and insulin
    resistance remain incompletely defined.
  biological_scale: ORGANISM
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  biological_processes:
  - preferred_term: glucose homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0042593
      label: glucose homeostasis
  - preferred_term: insulin receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
  locations:
  - preferred_term: adipose tissue
    term:
      id: UBERON:0001013
      label: adipose tissue
  evidence:
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These phenotypes suggest the physiological role of estrogens on the skeleton, on pituitary function, on the reproductive system, on glucose metabolism, being the precise mechanism on each of these functions not yet known in detail."
    explanation: >-
      Review-level evidence supports glucose-metabolism involvement while
      acknowledging unresolved intermediates.
  - reference: PMID:19844120
    reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Insulin sensitivity may be abnormal in both men and women."
    explanation: >-
      Supports insulin-sensitivity abnormality across sexes.
  downstream:
  - target: Insulin Resistance
    description: >-
      Estrogen-deficiency effects on glucose metabolism can manifest as reduced
      insulin sensitivity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Unresolved estrogen-dependent glucose-metabolism pathways.
    evidence:
    - reference: PMID:19844120
      reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Insulin sensitivity may be abnormal in both men and women."
      explanation: >-
        Supports insulin-sensitivity abnormality as a metabolic manifestation of
        aromatase deficiency.
  - target: Obesity
    description: >-
      Estrogen-deficient metabolic dysregulation can include excess adiposity,
      although the responsible tissue intermediates are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
      explanation: The clinical review lists abdominal obesity in the metabolic spectrum.
  - target: Acanthosis Nigricans
    description: >-
      Acanthosis nigricans can accompany the insulin-resistant metabolic
      phenotype of congenital estrogen deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Insulin resistance and compensatory hyperinsulinemia.
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
      explanation: The clinical review lists acanthosis nigricans with insulin resistance.
  - target: Hyperlipidemia
    description: >-
      Dyslipidemia can accompany the metabolic effects of congenital estrogen
      deficiency.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
      explanation: The clinical review lists dyslipidemia in the metabolic spectrum.
  - target: Hepatic Steatosis
    description: >-
      Hepatic steatosis can accompany the broader metabolic phenotype, but the
      estrogen-dependent liver intermediates remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
      explanation: The clinical review lists non-alcoholic fatty liver.
  - target: Type II Diabetes Mellitus
    description: >-
      Type II diabetes is reported in the metabolic spectrum, but progression
      from insulin resistance is incompletely characterized in this ultra-rare
      disorder.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Persistent insulin resistance and impaired glucose tolerance.
    evidence:
    - reference: ORPHA:91
      reference_title: Aromatase deficiency
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0005978 | Type II diabetes mellitus | Frequent (79-30%)"
      explanation: >-
        Orphanet supports the clinical association and frequency; the
        insulin-resistance intermediate is a mechanistic interpretation.
phenotypes:
- category: Reproductive
  name: Ambiguous Genitalia
  description: >-
    Virilized or atypical external genitalia in 46,XX individuals caused by
    prenatal androgen excess when placental/fetal aromatization is deficient.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: In 46,XX individuals.
  phenotype_term:
    preferred_term: Ambiguous genitalia, female
    term:
      id: HP:0000061
      label: Ambiguous genitalia, female
  evidence:
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
    explanation: >-
      Systematic review count supports ambiguous genitalia as very frequent in
      genetically confirmed 46,XX aromatase deficiency.
- category: Reproductive
  name: Maternal Antenatal Virilization
  description: >-
    Virilization of the pregnant mother can occur when the fetal-placental unit
    cannot aromatize androgen precursors to estrogens, leading to excess
    androgen exposure during affected pregnancies.
  frequency: FREQUENT
  notes: Maternal manifestation during pregnancy with an affected fetus.
  evidence:
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
    explanation: >-
      The systematic review count supports maternal antenatal virilization as a
      frequent presentation associated with aromatase deficiency pregnancies.
  - reference: PMID:40321354
    reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 10-day-old newborn presented with atypical genitalia and a history of maternal virilization during pregnancy.
    explanation: >-
      Case-report evidence documents maternal virilization during pregnancy in
      an infant with genetically confirmed aromatase deficiency.
- category: Reproductive
  name: Clitoromegaly
  description: Enlarged clitoris due to androgen excess in 46,XX individuals.
  notes: Component of 46,XX virilization.
  phenotype_term:
    preferred_term: Clitoral hypertrophy
    term:
      id: HP:0008665
      label: Clitoral hypertrophy
  evidence:
  - reference: PMID:24482950
    reference_title: "Aromatase deficiency: an unusual cause for primary amenorrhea with virilization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She lacked feminine secondary sexual characters, had eunuchoid body habitus and prominent clitoromegaly."
    explanation: >-
      Human case report directly supports prominent clitoromegaly in a 46,XX
      affected individual.
- category: Reproductive
  name: Delayed Puberty
  description: >-
    Poor or delayed development of secondary sexual characteristics due to
    estrogen deficiency.
  diagnostic: true
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:11305285
    reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
    explanation: >-
      Supports pubertal failure/poor pubertal development in 46,XX individuals.
- category: Reproductive
  name: Hypergonadotropic Hypogonadism
  description: >-
    Elevated gonadotropin levels with inadequate gonadal function due to loss of
    estrogen feedback and impaired reproductive maturation.
  diagnostic: true
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypergonadotropic hypogonadism
    term:
      id: HP:0000815
      label: Hypergonadotropic hypogonadism
  evidence:
  - reference: PMID:11305285
    reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
    explanation: >-
      Directly supports hypergonadotropic hypogonadism at puberty in affected
      girls.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000815 | Hypergonadotropic hypogonadism | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Reproductive
  name: Primary Amenorrhea
  description: >-
    Absence of menarche due to estrogen deficiency preventing normal pubertal
    and endometrial development.
  notes: In 46,XX individuals.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Primary amenorrhea
    term:
      id: HP:0000786
      label: Primary amenorrhea
  evidence:
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At puberty they show primary amenorrhea, no breast development, worsening of the virilization and the absence of growth spurt."
    explanation: >-
      Directly supports primary amenorrhea in affected females at puberty.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000786 | Primary amenorrhea | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Reproductive
  name: Ovarian Cysts
  description: >-
    Ovarian cysts associated with elevated gonadotropins and ovarian androgen
    excess in 46,XX aromatase deficiency.
  frequency: FREQUENT
  notes: In 46,XX individuals.
  phenotype_term:
    preferred_term: Ovarian cyst
    term:
      id: HP:0000138
      label: Ovarian cyst
  evidence:
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
    explanation: >-
      The 13/30 ovarian-cyst frequency supports the FREQUENT band.
- category: Reproductive
  name: Female infertility
  description: >-
    Infertility in affected 46,XX individuals reflects estrogen-deficient
    reproductive development and ovarian dysfunction.
  frequency: VERY_FREQUENT
  notes: In 46,XX individuals.
  phenotype_term:
    preferred_term: Female infertility
    term:
      id: HP:0008222
      label: Female infertility
  evidence:
  - reference: ORPHA:91
    reference_title: "Aromatase deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0008222 | Female infertility | Very frequent (99-80%)"
    explanation: Orphanet reports female infertility as very frequent.
- category: Reproductive
  name: Male infertility
  description: >-
    Infertility in affected 46,XY individuals is part of the reproductive
    phenotype of congenital estrogen deficiency.
  frequency: VERY_FREQUENT
  notes: In 46,XY individuals.
  phenotype_term:
    preferred_term: Male infertility
    term:
      id: HP:0003251
      label: Male infertility
  evidence:
  - reference: ORPHA:91
    reference_title: "Aromatase deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003251 | Male infertility | Very frequent (99-80%)"
    explanation: Orphanet reports male infertility as very frequent.
- category: Integumentary
  name: Generalized Hirsutism
  description: >-
    Generalized terminal-hair growth can occur with persistent androgen excess,
    particularly in affected 46,XX individuals.
  frequency: FREQUENT
  notes: Most relevant to the androgen-excess phenotype in 46,XX individuals.
  phenotype_term:
    preferred_term: Generalized hirsutism
    term:
      id: HP:0002230
      label: Generalized hirsutism
  evidence:
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002230 | Generalized hirsutism | Frequent (79-30%)"
    explanation: Orphanet records generalized hirsutism as frequent.
- category: Reproductive
  name: Cryptorchidism
  description: >-
    Undescended testis is reported in affected 46,XY individuals as part of the
    male reproductive phenotype.
  frequency: VERY_FREQUENT
  notes: In affected 46,XY individuals.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present.
    explanation: The clinical review within the case report lists cryptorchidism.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000028 | Cryptorchidism | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Reproductive
  name: Postpubertal Macroorchidism
  description: >-
    Increased testicular volume can emerge after puberty in affected 46,XY
    individuals.
  frequency: FREQUENT
  notes: In affected postpubertal 46,XY individuals.
  phenotype_term:
    preferred_term: Macroorchidism, postpubertal
    term:
      id: HP:0002050
      label: Macroorchidism, postpubertal
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal spermatogenesis, oligospermia, increase in testis volume, and cryptorchidism are often present.
    explanation: The clinical review within the case report describes increased testicular volume.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002050 | Macroorchidism, postpubertal | Frequent (79-30%)"
    explanation: Orphanet supplies the frequent band.
- category: Musculoskeletal
  name: Delayed Skeletal Maturation
  description: >-
    Delayed bone age and persistent open epiphyses due to insufficient
    estrogen-mediated skeletal maturation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Delayed skeletal maturation
    term:
      id: HP:0002750
      label: Delayed skeletal maturation
  evidence:
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
    explanation: >-
      Systematic-review data support delayed bone age as a frequent skeletal
      finding.
- category: Musculoskeletal
  name: Delayed epiphyseal ossification
  description: >-
    Epiphyseal ossification is delayed when estrogen-dependent skeletal
    maturation and epiphyseal closure are impaired.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Delayed epiphyseal ossification
    term:
      id: HP:0002663
      label: Delayed epiphyseal ossification
  evidence:
  - reference: ORPHA:91
    reference_title: "Aromatase deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002663 | Delayed epiphyseal ossification | Very frequent (99-80%)"
    explanation: Orphanet reports delayed epiphyseal ossification as very frequent.
- category: Musculoskeletal
  name: Tall Stature
  description: >-
    Continued linear growth beyond the usual age of epiphyseal closure,
    especially in 46,XY affected individuals.
  frequency: VERY_FREQUENT
  notes: Most characteristic in affected 46,XY individuals.
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: PMID:11305285
    reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These men are extremely tall and have eunuchoid proportions with continued linear growth into adulthood, lack of epiphyseal closure, and osteoporosis due to estrogen deficiency."
    explanation: >-
      Directly supports tall stature from continued linear growth in
      aromatase-deficient men.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000098 | Tall stature | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Musculoskeletal
  name: Osteoporosis
  description: >-
    Reduced bone mineral density and increased fracture risk resulting from
    inadequate estrogen-mediated bone remodeling and peak bone mass accrual.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:32623730
    reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
    explanation: >-
      The 5/8 count supports the low-bone-mass spectrum in reported 46,XX cases
      but does not distinguish osteopenia from osteoporosis.
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
    explanation: >-
      Review-level human evidence supports osteopenia/osteoporosis in affected
      males.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000939 | Osteoporosis | Very frequent (99-80%)"
    explanation: Orphanet supplies the phenotype-specific very-frequent band.
- category: Musculoskeletal
  name: Osteopenia
  description: >-
    Reduced bone mineral density may present as osteopenia in aromatase
    deficiency.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
  evidence:
  - reference: ORPHA:91
    reference_title: "Aromatase deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000938 | Osteopenia | Very frequent (99-80%)"
    explanation: Orphanet reports osteopenia as very frequent.
- category: Musculoskeletal
  name: Eunuchoid Habitus
  description: >-
    Disproportionately long limbs result from persistent appendicular growth
    after the usual age of epiphyseal closure.
  frequency: VERY_FREQUENT
  notes: Most characteristic in affected 46,XY adults.
  phenotype_term:
    preferred_term: Eunuchoid habitus
    term:
      id: HP:0003782
      label: Eunuchoid habitus
  evidence:
  - reference: PMID:19707181
    reference_title: "Aromatase deficiency in men: a clinical perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At presentation, all men with aromatase deficiency have tall stature, delayed bone maturation, osteopenia or osteoporosis and eunuchoid skeletal proportions.
    explanation: The male clinical review directly supports eunuchoid proportions.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003782 | Eunuchoid habitus | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Musculoskeletal
  name: Bone Pain
  description: >-
    Bone pain can accompany low bone mass and recurrent low-trauma fractures.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient was a 27-year-old male who presented with bone pain, recurrent bone fractures associated with minimal trauma starting in puberty, and a progressive increase in height.
    explanation: An affected adult presented with bone pain and recurrent low-trauma fractures.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002653 | Bone pain | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Musculoskeletal
  name: Genu Valgum
  description: >-
    Knock-knee deformity is part of the reported skeletal spectrum.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Genu valgum
    term:
      id: HP:0002857
      label: Genu valgum
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical and radiological findings include delay in bone maturation, lack of epiphyseal closure, continuation of linear growth, tall stature, eunuchoid body habitus, genu valgum, bone pain, osteopenia, and osteoporosis.
    explanation: The clinical review within the case report lists genu valgum.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002857 | Genu valgum | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Metabolic
  name: Insulin Resistance
  description: >-
    Reduced insulin sensitivity or glucose-insulin impairment associated with
    congenital estrogen deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: PMID:19844120
    reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Insulin sensitivity may be abnormal in both men and women."
    explanation: >-
      Supports abnormal insulin sensitivity as a metabolic manifestation.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000855 | Insulin resistance | Frequent (79-30%)"
    explanation: Orphanet supplies the frequent band.
- category: Metabolic
  name: Obesity
  description: >-
    Excess adiposity can accompany the metabolic phenotype of congenital
    estrogen deficiency.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
    explanation: The clinical review lists abdominal obesity in the metabolic spectrum.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001513 | Obesity | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Integumentary
  name: Acanthosis Nigricans
  description: >-
    Acanthosis nigricans can accompany the insulin-resistant metabolic
    phenotype.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
    explanation: The clinical review lists acanthosis nigricans.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000956 | Acanthosis nigricans | Frequent (79-30%)"
    explanation: Orphanet supplies the frequent band.
- category: Metabolic
  name: Hyperlipidemia
  description: Dyslipidemia can accompany congenital estrogen deficiency.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperlipidemia
    term:
      id: HP:0003077
      label: Hyperlipidemia
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
    explanation: The clinical review lists dyslipidemia.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003077 | Hyperlipidemia | Very frequent (99-80%)"
    explanation: Orphanet supplies the very-frequent band.
- category: Digestive
  name: Hepatic Steatosis
  description: >-
    Non-alcoholic hepatic steatosis can occur as part of the metabolic
    phenotype.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic syndrome findings such as abdominal obesity, insulin resistance, impaired glucose tolerance, acanthosis nigricans, non-alcoholic fatty liver, and dyslipidemia develop at early ages (1,4,8).
    explanation: The clinical review lists non-alcoholic fatty liver.
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001397 | Hepatic steatosis | Frequent (79-30%)"
    explanation: Orphanet supplies the frequent band.
- category: Endocrine
  name: Type II Diabetes Mellitus
  description: >-
    Type II diabetes can occur in the insulin-resistant metabolic spectrum.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
  evidence:
  - reference: ORPHA:91
    reference_title: Aromatase deficiency
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005978 | Type II diabetes mellitus | Frequent (79-30%)"
    explanation: Orphanet records type II diabetes mellitus as frequent.
genetic:
- name: CYP19A1
  gene_term:
    preferred_term: CYP19A1
    term:
      id: hgnc:2594
      label: CYP19A1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Biallelic loss-of-function variants in CYP19A1, which encodes aromatase,
    cause autosomal recessive aromatase deficiency.
  evidence:
  - reference: PMID:40321354
    reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aromatase deficiency is a rare autosomal recessive condition due to a mutation in the CYP19A1 encoding aromatase enzyme."
    explanation: >-
      Confirms CYP19A1 variants as the cause of aromatase deficiency.
  - reference: PMID:34348419
    reference_title: "Aromatase deficiency in an Ontario Old Order Mennonite family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our proband is an Old Order Mennonite female born with ambiguous genitalia who was identified to carry novel homozygous variant in the CYP19A1 gene c.1304G>A (p. Arg435His)."
    explanation: >-
      Reports a homozygous CYP19A1 variant in an affected individual.
biochemical:
- name: Serum Estradiol
  presence: DECREASED
  context: >-
    Estradiol is very low or undetectable because aromatase cannot efficiently
    convert androgens to estrogens.
  biomarker_term:
    preferred_term: estradiol
    term:
      id: CHEBI:23965
      label: estradiol
  readouts:
  - target: CYP19A1 Loss-of-Function and Aromatase Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Very low or undetectable estradiol reports the aromatase enzyme block.
    evidence:
    - reference: PMID:35837780
      reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        His estradiol was below the measurable line, the follicle-stimulating hormone (FSH) increased, bone age delayed, epiphysis unfused, and the bone mass reduced.
      explanation: Undetectable estradiol directly reports the aromatase block.
  - target: Estrogen Deficiency and Androgen Excess
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low serum estradiol directly reports the estrogen-deficient endocrine state.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
      explanation: The review directly links the genotype to absent estrogen synthesis.
  evidence:
  - reference: PMID:35837780
    reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      His estradiol was below the measurable line, the follicle-stimulating hormone (FSH) increased, bone age delayed, epiphysis unfused, and the bone mass reduced.
    explanation: >-
      Human case report supports very low estradiol with elevated FSH and
      skeletal findings.
  - reference: PMID:19707181
    reference_title: "Aromatase deficiency in men: a clinical perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
    explanation: >-
      Review-level clinical guidance supports undetectable serum estradiol as a
      diagnostic biochemical feature.
- name: Serum Testosterone
  presence: INCREASED
  context: >-
    Testosterone is normal to elevated because androgen precursors are not
    efficiently aromatized to estrogens.
  biomarker_term:
    preferred_term: testosterone
    term:
      id: CHEBI:17347
      label: testosterone
  readouts:
  - target: Estrogen Deficiency and Androgen Excess
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Normal-to-elevated circulating testosterone reports androgen excess from failed aromatization.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
      explanation: The review directly supports normal-to-elevated circulating testosterone.
  evidence:
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
    explanation: >-
      Supports normal-to-elevated testosterone in aromatase deficiency.
- name: Serum Follicle-Stimulating Hormone
  presence: INCREASED
  context: >-
    FSH can be elevated because low estrogen weakens negative feedback on the
    hypothalamic-pituitary-gonadal axis.
  biomarker_term:
    preferred_term: Follicle stimulating hormone
    term:
      id: CHEBI:81569
      label: Follicle stimulating hormone
  readouts:
  - target: Gonadotropin Feedback and Reproductive Development Disruption
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated serum FSH reports disrupted gonadal feedback.
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable.
      explanation: The affected adult had serum FSH above normal.
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable.
    explanation: The affected adult had serum FSH above normal.
- name: Serum Luteinizing Hormone
  presence: INCREASED
  context: >-
    LH can be elevated because low estrogen weakens negative feedback on the
    hypothalamic-pituitary-gonadal axis.
  biomarker_term:
    preferred_term: Luteinizing hormone
    term:
      id: CHEBI:81568
      label: Luteinizing hormone
  readouts:
  - target: Gonadotropin Feedback and Reproductive Development Disruption
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated serum LH reports disrupted gonadal feedback.
    evidence:
    - reference: PMID:23748068
      reference_title: "Aromatase deficiency, a rare syndrome: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable.
      explanation: The affected adult had serum LH above normal.
  evidence:
  - reference: PMID:23748068
    reference_title: "Aromatase deficiency, a rare syndrome: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable.
    explanation: The affected adult had serum LH above normal.
diagnosis:
- name: CYP19A1 Sequencing and Endocrine Profile
  description: >-
    Diagnosis is supported by low or undetectable estradiol, elevated
    gonadotropins or androgen excess depending on age and sex, and confirmation
    by CYP19A1 sequencing.
  presence: Positive in affected individuals
  evidence:
  - reference: PMID:19707181
    reference_title: "Aromatase deficiency in men: a clinical perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
    explanation: >-
      Supports the combined biochemical, skeletal, and genetic diagnostic
      approach.
  - reference: PMID:25415177
    reference_title: "Five new cases of 46,XX aromatase deficiency: clinical follow-up from birth to puberty, a novel mutation, and a founder effect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Direct sequencing of the CYP19A1 gene from genomic DNA revealed one novel mutation (c.574C>T) in two patients."
    explanation: >-
      Demonstrates diagnostic CYP19A1 sequencing in affected 46,XX patients.
treatments:
- name: Estrogen Replacement Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Estradiol replacement restores estrogen exposure, supports skeletal
    maturation and epiphyseal closure, and is the central disease-directed
    therapy once aromatase deficiency is diagnosed.
  treatment_term:
    preferred_term: Estrogen Replacement Therapy
    description: Therapeutic administration of estrogen to replace deficient endogenous hormone production.
    term:
      id: NCIT:C15231
      label: Estrogen Replacement Therapy
    therapeutic_agent:
    - preferred_term: estradiol
      term:
        id: CHEBI:23965
        label: estradiol
  target_phenotypes:
  - preferred_term: Delayed skeletal maturation
    term:
      id: HP:0002750
      label: Delayed skeletal maturation
  - preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
  - preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:18448329
    reference_title: "Human models of aromatase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
    explanation: >-
      Supports estradiol replacement as disease-directed therapy for skeletal
      maturation.
  - reference: PMID:19707181
    reference_title: "Aromatase deficiency in men: a clinical perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy."
    explanation: >-
      Clinical review supports lifelong estradiol replacement therapy in
      affected males.
  target_mechanisms:
  - target: Estrogen Deficiency and Androgen Excess
    treatment_effect: RESTORES
    description: Estradiol replacement restores downstream estrogen exposure despite persistent CYP19A1 deficiency.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
      explanation: >-
        Clinical response to estradiol replacement supports restoration of
        estrogen-dependent downstream physiology.
  - target: Impaired Skeletal Maturation and Bone Remodeling
    treatment_effect: RESTORES
    description: Estradiol replacement promotes epiphyseal closure and skeletal maturation.
    evidence:
    - reference: PMID:18448329
      reference_title: "Human models of aromatase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
      explanation: >-
        Directly supports restoration of skeletal maturation with estradiol
        replacement.
📚

References & Deep Research

Deep Research

2
Disorder ▸

Disorder

  • Name: Aromatase Deficiency
  • Category: Genetic
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 51

Key Pathophysiology Nodes

  • CYP19A1 Gene Mutation
  • Estrogen Deficiency
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1152/physiol.00054.2015
  • DOI:10.3389/fendo.2023.1226387
  • DOI:10.3389/fendo.2024.1354759
  • DOI:10.3389/fendo.2024.1402579
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 11 citations 2025-12-15T09:09:45.955582

Disease Pathophysiology Research Report

Target Disease - Disease Name: Aromatase Deficiency (CYP19A1 loss-of-function) - MONDO ID: MONDO:0009735 (Aromatase deficiency; if subtyping required, consult ontology updates) - Category: Genetic (autosomal recessive disorder of steroidogenesis)

Pathophysiology description Aromatase deficiency is caused by biallelic pathogenic variants in CYP19A1 encoding microsomal aromatase (P450 19A1), the enzyme that converts C19 androgens (androstenedione, testosterone, 16α‑OH‑DHEA) into C18 estrogens (estrone, estradiol, estriol). Placental, gonadal, adipose, bone, brain, and other tissue expression means loss of aromatase produces systemic estrogen deficiency with accumulation of androgens. In pregnancy, failure of placental aromatase prevents conversion of fetal adrenal precursors (notably 16‑OH‑DHEAS) to estriol, allowing maternal exposure to androgen excess and leading to maternal virilization; concurrently, female (46,XX) fetuses are virilized by excess androgens. Core downstream effects include disruption of estrogen receptor signaling (ESR1/ESR2/GPER), disinhibited hypothalamic–pituitary–gonadal (HPG) axis drive (hypergonadotropic hypogonadism), impaired bone maturation and remodeling (delayed epiphyseal fusion, low bone mass), and adverse metabolic profiles (insulin resistance, dyslipidemia). “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess,” and placental/fetal aromatase normally “protects the mother from virilization” by metabolizing fetal androgens; deficiency therefore causes maternal and fetal virilization with very low estrogens and elevated androgens (46,XX DSD) (abalı2024diagnosisandmanagement pages 1-2, abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9). The clinical physiology of complete aromatase loss includes 46,XX ambiguous genitalia at birth, progressive virilization, and in both sexes estrogen‑dependent bone effects such as “delayed epiphyseal closure and osteopenia/osteoporosis,” with tall stature described in males due to unfused epiphyses (blakemore2016aromatasecontributionsto pages 5-7).

Core Pathophysiology - Primary mechanisms: loss of aromatase-mediated androgen→estrogen conversion; prenatal placental failure of estriol synthesis; systemic estrogen deficiency with androgen excess (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Dysregulated pathways: steroidogenesis flux (C19 accumulation), estrogen receptor signaling (ESR1/ESR2/GPER), HPG feedback (↑LH/FSH from low estrogen), bone remodeling (↑RANKL signaling with hypoestrogenism), metabolic regulation (insulin sensitivity, lipid homeostasis) (blakemore2016aromatasecontributionsto pages 5-7, abalı2024diagnosisandmanagement pages 5-6). - Affected cellular processes: ER-resident P450 catalysis; ligand-activated transcription via nuclear ERs; membrane-initiated estrogen signaling; endochondral ossification and growth plate fusion; ovarian folliculogenesis dependent on granulosa aromatase (blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9).

Key Molecular Players - Genes/Proteins (HGNC): CYP19A1/AROMATASE (HGNC:2594) causal; ERs ESR1 (HGNC:3467), ESR2 (HGNC:3468) and GPER1 (HGNC:4485) as signaling mediators; POR (HGNC:9208) as differential diagnosis affecting multiple microsomal P450s including CYP19A1; NR5A1 (HGNC:2510) may modify DSD phenotypes but is not causal in AroD (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7). - Chemical entities (CHEBI): androgens (androstenedione CHEBI:28689; testosterone CHEBI:17347) accumulate; estrogens (estrone CHEBI:17263; estradiol CHEBI:16469; estriol CHEBI:16490) are reduced; fetal precursor DHEA-S (CHEBI:28941) normally feeds placental estriol synthesis; antiandrogens (flutamide CHEBI:5102; spironolactone CHEBI:9606) are used adjunctively (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Cell types (CL): granulosa cells (ovarian estrogen synthesis); trophoblast (placental aromatase and maternal protection); Leydig cells (androgen production); osteoblasts/osteoclasts (bone remodeling under estrogen control); adipocytes (peripheral aromatization) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7). - Anatomical locations (UBERON): ovary, placenta, uterus, testis, bone, adipose tissue, brain are key affected sites (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).

Biological Processes (GO) - Steroid biosynthetic process (GO:0006694); estrogen biosynthetic process (GO:0006703) directly impaired by CYP19A1 loss (stancampiano202446xxdifferencesof pages 8-9). - Androgen metabolic process (GO:0008209) with accumulation of C19 substrates (abalı2024diagnosisandmanagement pages 1-2). - Estrogen receptor signaling pathway (GO:0030520) diminished systemically (blakemore2016aromatasecontributionsto pages 5-7). - Regulation of gonadotropin secretion (GO:0032274) disrupted, producing hypergonadotropic hypogonadism (blakemore2016aromatasecontributionsto pages 5-7). - Bone remodeling (GO:0046849) and endochondral ossification (GO:0001958) altered with delayed epiphyseal closure (blakemore2016aromatasecontributionsto pages 5-7).

Cellular Components - Endoplasmic reticulum membrane (GO:0005789) and microsomes (GO:0005792) host aromatase catalysis; estrogen receptors act at plasma membrane (GPER1) and nucleus (ESR1/ESR2), with systemic effects mediated via the extracellular hormone milieu (GO:0005886, GO:0005634, GO:0005615) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).

Disease Progression - Fetal: placental aromatase failure → maternal virilization in pregnancy; 46,XX fetal virilization due to transplacental and fetal androgen excess; estriol production markedly reduced (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Neonatal/Childhood: 46,XX ambiguous genitalia (clitoromegaly, posterior labial fusion, urogenital sinus); elevated androgens, very low estrogens; ovarian changes may include enlarged/multicystic or hypoplastic ovaries (abalı2024diagnosisandmanagement pages 5-6). - Puberty: hypergonadotropic hypogonadism with delayed/absent thelarche; progressive virilization if untreated; residual activity variants may show partial breast development (abalı2024diagnosisandmanagement pages 5-6). - Adulthood: fertility impairment in 46,XX; bone health complications (low BMD, delayed epiphyseal closure); metabolic features (insulin resistance, dyslipidemia) (blakemore2016aromatasecontributionsto pages 5-7, abalı2024diagnosisandmanagement pages 5-6).

Phenotypic Manifestations - 46,XX: prenatal virilization with ambiguous genitalia; pubertal failure with amenorrhea and hypergonadotropic hypogonadism; ovarian macrocysts or multicystic ovaries; progressive virilization; reduced estradiol with elevated androgens (abalı2024diagnosisandmanagement pages 5-6, abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9). - 46,XY: external genitalia typically normal or mildly affected; prominent estrogen-deficiency skeletal findings (tall stature, delayed epiphyseal closure, osteopenia/osteoporosis), reduced libido; metabolic derangements (blakemore2016aromatasecontributionsto pages 5-7).

Current applications and real-world implementations - Diagnostics: LC–MS/MS steroid profiling to demonstrate elevated C19 androgens with very low estrogens; genetic testing via targeted CYP19A1 sequencing or exome/genome sequencing; crucial differential diagnosis with POR deficiency (which reduces CYP19A1 activity secondarily) using gene testing and distinctive steroid profiles; prenatal suspicion with maternal virilization and low estriol (abalı2024diagnosisandmanagement pages 4-5, abalı2024diagnosisandmanagement pages 1-2). - Management: estrogen replacement therapy for pubertal induction and maintenance in 46,XX; consider antiandrogens (e.g., flutamide, spironolactone) to mitigate virilization; monitor and treat bone health in both sexes; fertility management is individualized, with limited long-term outcome data (abalı2024diagnosisandmanagement pages 5-6, blakemore2016aromatasecontributionsto pages 5-7). Expert reviews emphasize that estrogen replacement can improve ovarian phenotype (e.g., cyst resolution) and hypogonadism, though evidence remains from case-level data (abalı2024diagnosisandmanagement pages 5-6).

Expert opinions and recent developments (2023–2024) - 2024 DSD reviews place aromatase deficiency among non-CAH 46,XX DSD etiologies and stress advances in cytogenetic and molecular diagnostics; they reaffirm that “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess,” and that prenatal-onset androgen excess drives the 46,XX phenotype, with management challenges persisting due to rarity and heterogeneity (published 15 May 2024; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2024.1354759) (abalı2024diagnosisandmanagement pages 1-2). - A 2024 review of 46,XX DSDs outside CAH summarizes CYP19A1 genetics, tissue-specific expression, and placental metabolism of fetal 16‑OH‑DHEAS to estriol, underscoring the mechanistic basis of maternal/fetal virilization in aromatase deficiency (published May 2024; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2024.1402579) (stancampiano202446xxdifferencesof pages 8-9). - Differential with POR deficiency (2023 review) remains clinically salient since POR defects can cause “placental aromatase deficiency affected by POR,” necessitating distinct management pathways (published Aug 2023; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2023.1226387) (abalı2024diagnosisandmanagement pages 4-5). - Foundational expert synthesis (Physiology 2016) continues to frame the phenotype spectrum and systemic estrogen roles in bone and metabolism, with quotations widely cited in current reviews for skeletal and metabolic consequences of aromatase loss (published Jul 2016; https://doi.org/10.1152/physiol.00054.2015) (blakemore2016aromatasecontributionsto pages 5-7).

Relevant statistics and data - Case accrual remains limited; a 2024 review cites approximately 40 reported cases since the first description in 1991, reflecting the rarity of confirmed CYP19A1 biallelic loss-of-function (published May 2024) (stancampiano202446xxdifferencesof pages 8-9). - Biochemical hallmarks summarized in recent reviews include “elevated plasma androstenedione and testosterone with very low or undetectable estrone/estradiol,” consistent across reported cases (abalı2024diagnosisandmanagement pages 5-6).

Direct quotes supporting key statements - “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess.” (Frontiers in Endocrinology, 15 May 2024; https://doi.org/10.3389/fendo.2024.1354759) (abalı2024diagnosisandmanagement pages 1-2). - Placental aromatase “protects the mother from virilization,” so deficiency leads to maternal and fetal virilization (summarized in 2024 reviews) (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9). - Clinical physiology includes “delayed epiphyseal closure and osteopenia/osteoporosis” with tall stature in males (Physiology, Jul 2016; https://doi.org/10.1152/physiol.00054.2015) (blakemore2016aromatasecontributionsto pages 5-7).

Gene/protein annotations with ontology terms - CYP19A1 (HGNC:2594): aromatase, ER membrane P450; GO:0006703, GO:0006694; components GO:0005789/GO:0005792 (stancampiano202446xxdifferencesof pages 8-9). - ESR1 (HGNC:3467), ESR2 (HGNC:3468), GPER1 (HGNC:4485): estrogen signaling; GO:0030520; nucleus GO:0005634; plasma membrane GO:0005886 (blakemore2016aromatasecontributionsto pages 5-7). - POR (HGNC:9208): electron donor to microsomal CYPs; differential that can mimic aromatase deficiency (abalı2024diagnosisandmanagement pages 4-5).

Phenotype associations (HP terms) - Ambiguous genitalia (HP:0000062), clitoromegaly (HP:0008665), primary amenorrhea (HP:0000786), hypergonadotropic hypogonadism (HP:0000045), ovarian cyst (HP:0000137), tall stature (HP:0000098), delayed epiphyseal closure (HP:0003070), osteoporosis (HP:0000939), insulin resistance (HP:0000855), dyslipidemia (HP:0003119) (abalı2024diagnosisandmanagement pages 5-6, blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9).

Cell type involvement (CL terms) - Granulosa cell (CL:0002320), trophoblast (CL:0000351), Leydig cell (CL:0000182), osteoblast (CL:0000062), osteoclast (CL:0000092), adipocyte (CL:0000136) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).

Anatomical locations (UBERON terms) - Ovary (UBERON:0000992), placenta (UBERON:0001987), uterus (UBERON:0000995), testis (UBERON:0000473), bone (UBERON:0001474), adipose (UBERON:0001013), brain (UBERON:0000955) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).

Chemical entities (CHEBI terms) - Androstenedione (CHEBI:28689), testosterone (CHEBI:17347), estrone (CHEBI:17263), estradiol (CHEBI:16469), estriol (CHEBI:16490), DHEA sulfate (CHEBI:28941), spironolactone (CHEBI:9606), flutamide (CHEBI:5102) (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2).

Embedded artifact | Category | Item (name) | Ontology ID | Notes on role in disease | |---|---|---:|---| | Gene / Protein | CYP19A1 | HGNC:2594 | Aromatase enzyme; loss causes androgen accumulation and estrogen deficiency. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Gene / Protein | ESR1 | HGNC:3467 | Estrogen receptor alpha mediates estrogen signaling; affected by low estrogen. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | ESR2 | HGNC:3468 | Estrogen receptor beta; tissue-specific estrogen responses diminished. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | GPER1 | HGNC:4485 | Membrane estrogen receptor mediating rapid signaling; hypoestrogenism reduces activity. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | NR5A1 | HGNC:2510 | Transcription factor in gonadal development; can modify DSD phenotypes. (stancampiano202446xxdifferencesof pages 8-9) | | Gene / Protein | POR | HGNC:9208 | Electron donor to microsomal CYPs; POR defects can phenocopy aromatase issues. (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Granulosa cell | CL:0002320 | Site of ovarian aromatase expression; estrogen synthesis is impaired. (stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Trophoblast | CL:0000351 | Placental aromatase site; loss causes maternal and fetal virilization. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Leydig cell | CL:0000182 | Testicular androgen source; peripheral aromatization affects systemic balance. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Osteoblast | CL:0000062 | Bone-forming cell; estrogen deficiency increases bone resorption risk. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Osteoclast | CL:0000092 | Bone-resorbing cell; activity increases when estrogen is low. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Adipocyte | CL:0000136 | Peripheral aromatase expression site; contributes to local estrogen production. (blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Ovary | UBERON:0000992 | Site of granulosa aromatase; ovarian development and fertility impacted. (stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Placenta | UBERON:0001987 | Crucial for fetal estrogen production; maternal virilization if deficient. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Uterus | UBERON:0000995 | Estrogen-dependent organ; hypoplasia and poor endometrial development possible. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Testis | UBERON:0000473 | Androgen source; 46,XY genital phenotype often milder than 46,XX. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Bone | UBERON:0001474 | Affected by estrogen deficiency causing delayed epiphyseal closure and osteopenia. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Adipose tissue | UBERON:0001013 | Expresses aromatase; loss alters metabolic regulation and lipid profiles. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Brain | UBERON:0000955 | Central estrogen actions on behavior and HPG axis signaling disrupted. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Steroid biosynthetic process | GO:0006694 | Overall steroidogenesis altered with accumulation of androgens. (stancampiano202446xxdifferencesof pages 8-9) | | Biological process | Estrogen biosynthetic process | GO:0006703 | Aromatase-catalyzed estrogen synthesis is impaired. (stancampiano202446xxdifferencesof pages 8-9) | | Biological process | Androgen metabolic process | GO:0008209 | Androgen metabolism shifts toward accumulation of C19 steroids. (abalı2024diagnosisandmanagement pages 1-2) | | Biological process | Estrogen receptor signaling pathway | GO:0030520 | Downstream estrogen signaling reduced, affecting multiple tissues. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Regulation of gonadotropin secretion | GO:0032274 | HPG feedback disrupted causing hypergonadotropic hypogonadism. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Bone remodeling | GO:0046849 | Imbalanced osteoblast/osteoclast activity leading to bone loss. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Endochondral ossification | GO:0001958 | Delayed epiphyseal closure due to low estrogen levels. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Endoplasmic reticulum membrane | GO:0005789 | Location of microsomal aromatase P450 enzyme. (stancampiano202446xxdifferencesof pages 8-9) | | Cellular component | Microsome | GO:0005792 | Subcellular fraction containing aromatase activity. (stancampiano202446xxdifferencesof pages 8-9) | | Cellular component | Plasma membrane | GO:0005886 | Location of membrane estrogen receptor GPER; signaling changes. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Nucleus | GO:0005634 | Nuclear ER-mediated transcriptional responses are impaired. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Extracellular space | GO:0005615 | Circulating steroid hormones and paracrine signaling altered. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Androstenedione | CHEBI:28689 | Major aromatase substrate; accumulates when enzyme deficient. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Testosterone | CHEBI:17347 | Substrate and androgenic effector causing virilization. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estrone | CHEBI:17263 | Estrogen product reduced leading to systemic hypoestrogenism. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estradiol | CHEBI:16469 | Primary active estrogen decreased causing multisystem effects. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estriol | CHEBI:16490 | Placental fetal estrogen reduced; derived from 16OH-DHEAS normally. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | DHEA sulfate | CHEBI:28941 | Fetal adrenal precursor feeding placental estrogen synthesis; altered flux. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Spironolactone | CHEBI:9606 | Anti-androgen sometimes used to reduce virilization (off-label). (abalı2024diagnosisandmanagement pages 1-2) | | Chemical entity | Flutamide | CHEBI:5102 | Androgen receptor antagonist used to counter virilization. (abalı2024diagnosisandmanagement pages 1-2) | | Phenotype | Ambiguous genitalia | HP:0000062 | 46,XX virilization leading to atypical external genitalia. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Clitoromegaly | HP:0008665 | Enlarged clitoris due to prenatal androgen exposure. (abalı2024diagnosisandmanagement pages 1-2) | | Phenotype | Primary amenorrhea | HP:0000786 | Absent menses from hypergonadotropic hypogonadism. (abalı2024diagnosisandmanagement pages 1-2, blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Hypergonadotropic hypogonadism | HP:0000045 | Elevated gonadotropins due to low estrogen negative feedback. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Ovarian cyst | HP:0000137 | Multicystic ovaries reported from unopposed gonadotropin stimulation. (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Tall stature | HP:0000098 | Delayed epiphyseal closure results in increased final height. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Delayed epiphyseal closure | HP:0003070 | Result of estrogen deficiency impairing growth plate fusion. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Osteoporosis | HP:0000939 | Low bone mass risk due to chronic hypoestrogenism. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Insulin resistance | HP:0000855 | Metabolic alterations including insulin resistance reported. (abalı2024diagnosisandmanagement pages 5-6, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Dyslipidemia | HP:0003119 | Adverse lipid profile associated with low aromatase activity. (blakemore2016aromatasecontributionsto pages 5-7) |

Table: Compact ontology table mapping key genes, cells, locations, processes, components, chemicals, and phenotypes relevant to aromatase (CYP19A1) deficiency, with concise functional notes and source citations for database use.

Evidence items (PMIDs/DOIs/URLs; publication dates) - Abalı ZY, Guran T. Diagnosis and management of non-CAH 46,XX DSD. Frontiers in Endocrinology. Published 15 May 2024. DOI: 10.3389/fendo.2024.1354759. URL: https://doi.org/10.3389/fendo.2024.1354759 (abalı2024diagnosisandmanagement pages 1-2). - Stancampiano MR, et al. 46,XX DSD outside CAH. Frontiers in Endocrinology. Published May 2024. DOI: 10.3389/fendo.2024.1402579. URL: https://doi.org/10.3389/fendo.2024.1402579 (stancampiano202446xxdifferencesof pages 8-9). - Wang C, Tian Q. POR deficiency review. Frontiers in Endocrinology. Published Aug 2023. DOI: 10.3389/fendo.2023.1226387. URL: https://doi.org/10.3389/fendo.2023.1226387 (abalı2024diagnosisandmanagement pages 4-5). - Blakemore J, Naftolin F. Aromatase: physiology and disease. Physiology. Published Jul 2016. DOI: 10.1152/physiol.00054.2015. URL: https://doi.org/10.1152/physiol.00054.2015 (blakemore2016aromatasecontributionsto pages 5-7).

Limitations and open questions The rarity of confirmed CYP19A1 biallelic cases limits robust natural history and interventional evidence; many management suggestions derive from small series and case reports. Contemporary reviews call for standardized diagnostic algorithms (LC–MS/MS, genomics) and longitudinal registries to clarify fertility outcomes and optimal timing/dosing of estrogen therapy (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9).

References

  1. (abalı2024diagnosisandmanagement pages 1-2): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.

  2. (abalı2024diagnosisandmanagement pages 4-5): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.

  3. (stancampiano202446xxdifferencesof pages 8-9): Marianna Rita Stancampiano, Silvia Laura Carla Meroni, Carmen Bucolo, and Gianni Russo. 46,xx differences of sex development outside congenital adrenal hyperplasia: pathogenesis, clinical aspects, puberty, sex hormone replacement therapy and fertility outcomes. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1402579, doi:10.3389/fendo.2024.1402579. This article has 8 citations and is from a poor quality or predatory journal.

  4. (blakemore2016aromatasecontributionsto pages 5-7): Jennifer Blakemore and Fredrick Naftolin. Aromatase: contributions to physiology and disease in women and men. Physiology, 31 4:258-69, Jul 2016. URL: https://doi.org/10.1152/physiol.00054.2015, doi:10.1152/physiol.00054.2015. This article has 240 citations and is from a peer-reviewed journal.

  5. (abalı2024diagnosisandmanagement pages 5-6): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.